For healthcare professionals
The page offers healthcare professionals information on proper use of prescription medications.
chugai-pharm.co.jpCrawled Nov 14, 2026
The page offers healthcare professionals information on proper use of prescription medications.
Bio Lab is a Chugai Pharma science experience facility for elementary to high school students, offering experiments and programs to foster interest in biology and biotechnology.
The page describes Duchenne Muscular Dystrophy (DMD), including symptoms, testing, care, and support resources for patients and families.
The page explains paroxysmal nocturnal hemoglobinuria (PNH), including symptoms, testing, treatment, and ongoing care information.
The page provides information to help patients and families use Chugai Pharma products correctly during or before treatment, emphasizing consultation with medical professionals.
Chugai pharma releases news about company-related updates, including medical products and development information, for stakeholders.
The page offers press releases, briefing materials, and announcements for media representatives.
Chugai pharma creates value through innovative pharmaceuticals and services, contributing to global healthcare and well-being.
The page outlines Chugai pharma’s policy and efforts to prevent harassment during recruitment activities.
The page lists recruitment opportunities for new graduates, mid-career professionals, and individuals with disabilities.
Chugai pharma introduces new graduate, career, and disability-inclusive hiring opportunities.
Chugai pharma develops pharmaceuticals and business activities to achieve sustainable, patient-centered healthcare.
Chugai pharma partners with Roche to deliver innovative pharmaceuticals and services globally using proprietary business models, technology, and science.
Chugai pharma collaborates externally to create innovative pharmaceuticals and services using proprietary technology, science, and new ideas.
The page provides shareholders and investors with financial reports, pipeline development, technology details, and investor-specific information.
The page shares stories of Chugai pharma employees pursuing continuous innovation for patient happiness.
The page provides access information for Chugai Life Science Park Yokohama, which houses the Bio Lab facility.
Chugai Pharma Group emphasizes compliance with laws, social values, and ethics, prioritizing corporate ethics over performance. Suspected violations can be reported via the Chugai Speak-Up Line.
Chugai Pharma involves patients in its medical product development teams.
Chugai Pharma is a research-driven pharmaceutical company leveraging its technology and science to develop innovative drugs and services for global healthcare.
Chugai Pharma is a research-driven pharmaceutical company leveraging its technology and science to develop innovative drugs and services for global healthcare.
Chugai Pharma Group collects and processes personal data to deliver innovative pharmaceuticals and services globally, adhering to ethical standards and regional regulations.
Chugai Pharma Group has established a privacy policy to handle personal data responsibly.
Chugai pharma uses social media to engage stakeholders and enhance corporate value through information sharing.
The website is operated by Chugai pharma or its agents; users must agree to the terms before accessing it.
Chugai Pharmaceutical reports a 19% increase in nine-month core profit to ¥536.1 billion, driven by a 17.2% revenue rise to ¥1,068.1 billion. The Roche-controlled Japanese drugmaker maintains its full-year forecast while trading shares decline 3.03% to ¥6,688. The CEO expresses confidence in surpassing annual targets despite market fluctuations.
Chugai Pharmaceutical Co. projects its annual financial results will exceed earlier forecasts, driven by strong performance in drug exports and royalty income. The company’s international sales and licensing agreements contribute to the optimistic outlook. Analysts monitor the impact on Chugai’s stock and related assets.
Chugai Pharmaceutical releases its fiscal 2026 third-quarter financial results on **October 27, 2026**, providing investors with an official update on operations. The company also receives the **Porter Prize 2026**, awarded for its drug discovery strategy and partnership with Roche. As of **October 21, 2026**, its stock trades at **EUR 36.73** on Lang & Schwarz.
Chugai reports robust first-half 2026 financial performance, driven by revenue growth and operational improvements. The company highlights expansion in its pharmaceutical portfolio, including key therapies. Analysts attribute the gains to strong demand for its existing treatments and new product contributions. Shares react positively, rising significantly following the earnings announcement.
Chugai Pharmaceutical includes its first-half 2026 financial results in Roche Group’s consolidated earnings report. The announcement clarifies how Chugai’s performance contributes to Roche’s overall financial reporting structure.